Cronos Group (Cronos Group) Debt-to-Equity

: 0.00 (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

Cronos Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.99 Mil. Cronos Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.56 Mil. Cronos Group's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $1,099.57 Mil. Cronos Group's debt to equity for the quarter that ended in Dec. 2023 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cronos Group's Debt-to-Equity or its related term are showing as below:

During the past 10 years, the highest Debt-to-Equity Ratio of Cronos Group was 0.13. The lowest was 0.00. And the median was 0.01.

CRON's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.29
* Ranked among companies with meaningful Debt-to-Equity only.

Cronos Group Debt-to-Equity Historical Data

The historical data trend for Cronos Group's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cronos Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.01

Cronos Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																-	-	-	-	-

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cronos Group Debt-to-Equity Distribution

For the Drug Manufacturers industry and Healthcare sector, Cronos Group's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cronos Group's Debt-to-Equity falls into.

Cronos Group Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cronos Group's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.994	+	1.559)	/	1099.571
	=	0.00

Cronos Group's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.994	+	1.559)	/	1099.571
	=	0.00

Cronos Group (NAS:CRON) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cronos Group Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cronos Group's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cronos Group (Cronos Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cronos Group Inc (NAS:CRON) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

7CI:Germany CRON:Canada

Address

111 Peter Street, Suite 300, Toronto, ON, CAN, M5V 2H1

Website

https://www.thecronosgroup.com

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.

Executives

Kamran Khan	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Elizabeth Seegar	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Dominik Meier	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Jason Marc Adler	director	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2G9
Mcginness James Andrew Iii	officer: VP, Controller	C/O MARKETWISE, 1125 N. CHARLES STREET, BALTIMORE MD 21201
Maple Holdco (bermuda) Ltd.	10 percent owner	C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Maple Acquireco (canada) Ulc	10 percent owner	C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Summit Llc	10 percent owner	C/O ALTRIA GROUP, INC., 6601 WEST BROAD STREET, RICHMOND VA 23230
Altria Group, Inc.	10 percent owner	6601 WEST BROAD STREET, RICHMOND VA 23230
James Holm	officer: Chief Financial Officer	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Arye Weigensberg	officer: See Remarks	111 PETER STREET, SUITE 300, TORONTO A6 MV5 2H1
Doucet Terrence Gregory Joseph	officer: See Remarks	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
John Griese	officer: See Remarks	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Ran Gorelik	officer: General Manager (Israel)	111 PETER STREET, SUITE 300, TORONTO A6 M5V 2H1
Robert L Madore	officer: Chief Financial Officer	C/O RALPH LAUREN CORPORATION, 650 MADISON AVENUE, NEW YORK NY 10022